By Olivia Bugault
Roche Holding AG said Thursday that its Phase 2/3 trial of Covid-19 treatment Ronapreve met its primary endpoint.
Results from the trial show that Ronapreve, which is a combination of two antibodies, casirivimab and imdevimab, "significantly" reduces the viral load within seven days in patients who have been hospitalized with Covid-19, the pharmaceutical company said.
"The efficacy and safety of Ronapreve have been studied across multiple Phase III clinical trials in non-hospitalized and hospitalized Covid-19 patients, and in the preventive setting," Roche said. "Ronapreve is currently not authorized in patients who are hospitalized due to Covid-19 infection," it said.
Write to Olivia Bugault at [email protected]
